Life Science

F0F1-ATPase and adenine nucleotide translocator inhibitor and GABA receptor antagonist. It prevents mitochondrial respiration and decreases sperm count and motility. Grade: &ge70%

F0F1-ATPase and adenine nucleotide translocator inhibitor and GABA receptor antagonist. It prevents mitochondrial respiration and decreases sperm count and motility. Grade: &ge70%

A mixture of the natural macrocyclic lactones avermectin B1a and avermectin B1b that has both insecticidal and anthelmintic actions.

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Progesterone derivative and Cyp17A1 inhibitor used to treat castration-resistant prostate cancer. It decreases androgen production and may inhibit eIF4F signaling.

Progesterone derivative and Cyp17A1 inhibitor used to treat castration-resistant prostate cancer. It decreases androgen production and may inhibit eIF4F signaling.

Progesterone derivative and Cyp17A1 inhibitor used to treat castration-resistant prostate cancer. It decreases androgen production and may inhibit eIF4F signaling.

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma